
Venture capital
Ascenta Capital
Ascenta Capital is a biotech-focused venture investor that makes concentrated investments in clinical-stage drug developers and supports management teams with strategic and operational experience.
Investment activity
Round-by-round activity is part of PRO
Key signal this week
Is Ascenta Capital right for your round?
Key stats
Fund cycle Public record
Fund vehicles on public registers (SEC adviser filings). Values are the gross assets each filing reports, not fund sizes.
Latest investments
BetaRounds Ascenta Capital joined, from press and the firm’s own posts.
1 round in the last 12 months
Round sizes, Ascenta Capital’s role and who invested alongside.
Notable portfolio
Portfolio and exits
Every company Ascenta Capital backed and how the exits played out.
Where the money goes
Share of companies at first investment, from the rounds we track.
Investment team
Where to meet Ascenta Capital
Events where Ascenta Capital’s team spoke or showed up, from event programmes, press and the firm’s own posts.
Signals
Register and fund filings are free. Website, team and portfolio changes we pick up are PRO.
Founders also look at
Frequently asked questions
Ascenta Capital is based in the United States.
6 fund vehicles are on public registers (SEC adviser filings), including ASCENTA CAPITAL FUND I, L.P., ASCENTA CAPITAL PROJECT IKIGAI SPV, L.P. and ASCENTA CAPITAL PROJECT HENRI SPV, L.P.
Sectors: Biotech, Life sciences. From the firm’s own website.
Backs science-driven biotech companies as they move from preclinical work into early human trials, partnering on candidates in Phase 1 and 2 and on multi-medicine platforms. Makes concentrated bets, keeps patient needs central, and offers strategic guidance, connections and resources beyond capital. From the firm’s own website.
Ascenta Capital lists 11 portfolio companies on its website, including ADARx Pharmaceuticals, Alpha-9 Oncology, Angitia, Cardurion Pharmaceuticals and Iambic Therapeutics.
Firms whose websites list some of the same companies include Atlas Venture, Delos Capital and Catalio Capital Management.
Know before Ascenta Capital’s next round is announced.
PRO tracks Ascenta Capital’s filings, hires and portfolio changes the day they land, alongside 3,869 other firms.